B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
- Authors
- Alam, M.; Ali, S.; Mohammad, T.; Hasan, G.M.; Yadav, D.K.; Hassan, M.I.
- Issue Date
- Oct-2021
- Publisher
- MDPI
- Keywords
- Apoptosis; B cell lymphoma 2; Cancers; Clinical trials; Inhibitors; Targeted therapy
- Citation
- International Journal of Molecular Sciences, v.22, no.19
- Journal Title
- International Journal of Molecular Sciences
- Volume
- 22
- Number
- 19
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/82559
- DOI
- 10.3390/ijms221910442
- ISSN
- 1661-6596
- Abstract
- Defects in the apoptosis mechanism stimulate cancer cell growth and survival. B cell lymphoma 2 (Bcl-2) is an anti-apoptotic molecule that plays a central role in apoptosis. Bcl-2 is the founding constituent of the Bcl-2 protein family of apoptosis controllers, the primary apoptosis regulators linked with cancer. Bcl-2 has been identified as being over-expressed in several cancers. Bcl-2 is induced by protein kinases and several signaling molecules which stimulate cancer development. Identifying the important function played by Bcl-2 in cancer progression and development, and treatment made it a target related to therapy for multiple cancers. Among the various strategies that have been proposed to block Bcl-2, BH3-mimetics have appeared as a novel group of compounds thanks to their favorable effects on many cancers within several clinical settings. Because of the fundamental function of Bcl-2 in the regulation of apoptosis, the Bcl-2 protein is a potent target for the development of novel anti-tumor treatments. Bcl-2 inhibitors have been used against several cancers and provide a pre-clinical platform for testing novel therapeutic drugs. Clinical trials of multiple investigational agents targeting Bcl-2 are ongoing. This review discusses the role of Bcl-2 in cancer development; it could be exploited as a potential target for developing novel therapeutic strategies to combat various types of cancers. We further highlight the therapeutic activity of Bcl-2 inhibitors and their implications for the therapeutic management of cancer. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 약학대학 > 약학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/82559)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.